Close
Close
Treatment Database
(R)-tetrahydrofuran-3-yl 4-(6-(5-(4-ethoxy-1-isopropylpiperidin-4-yl)pyridin-2-yl)pyrrolo[1,2-b]pyridazin-4-yl)piperazine-1-carboxylate sesquisuccinate
Trade Name not avaiable
Orphan Indication Fibrodysplasia ossificans progressiva
USA Market Approval
USA Designation Date 08-08-2019
Sponsor Blueprint Medicines Corporation
45 Sidney Street
Cambridge, Massachusetts, 02139
More about Fibrodysplasia ossificans progressiva
Free Newsletter
Related Videos
by Scott Harwood
427 views
by Abidemi Uruejoma
1,093 views
by Abidemi Uruejoma
680 views
by Abidemi Uruejoma
2,843 views